- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA (2006), EMA (2007))|
|International Nonproprietary Names|
|Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2|
|Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) , with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.
|GtoPdb PubChem SID||178103385|
|Search PubMed clinical trials||ranibizumab|
|Search PubMed titles||ranibizumab|
|Search PubMed titles/abstracts||ranibizumab|